What Happened

Researchers from Royal Columbian Hospital and Simon Fraser University have published findings from the CLiCK trial in the Journal of the American Medical Association (JAMA), revealing a significant reduction in complications among critically ill patients. The study, which examined central venous access devices commonly known as central lines, was presented by senior author Dr. Steven Reynolds at the American Thoracic Society International Conference on May 18, 2026, with the formal publication following on May 19, 2026. The trial was conducted across six Canadian hospitals, including Royal Columbian, 素里 Memorial, Royal Jubilee, Nanaimo Regional General, St. Boniface, and Burnaby Hospital. It involved 1,468 adult ICU patients in a triple-blind, multi-centre, cluster-randomized crossover design. The team tested a 4% tetrasodium ethylenediaminetetraacetic acid (t-EDTA) locking solution manufactured by SterileCare Inc. against a control group to measure the composite outcome of central-line complications. The results showed a statistically significant 32% reduction in complications, with the t-EDTA group experiencing 13.1 events per 1,000 catheter-days compared to 19.9 in the control group. No adverse events related to the study locking fluid were reported during the trial.

Why It Matters

Central-line complications can interrupt critical care delivery and necessitate additional treatments, directly impacting patient safety and hospital resource allocation. This study provides high-level evidence that a specific locking solution can mitigate these risks in real-world clinical settings. As noted by Karen Mueller, CEO of SterileCare Inc., health technologies must be tested in actual clinical environments before health systems can make informed decisions about broader adoption. The findings suggest a viable pathway to improve care standards for critically ill patients across Canadian intensive care units.

Local Vancouver / Burnaby Context

The CLiCK trial highlights the collaborative capacity of British Columbia’s healthcare infrastructure, bridging academic research and clinical practice. Royal Columbian Hospital in New Westminster and Simon Fraser University played pivotal roles, with Dr. Steven Reynolds leading the clinical investigation and Marlena Ornowska, a research associate at SFU, serving as the first author. The involvement of Kate Keetch from Fraser Health’s Evaluation and Research Services underscores the regional health authority's commitment to evidence-based practice. Jeff Norris, President and CEO of the Royal Columbian Hospital Foundation, emphasized the study's relevance to the care provided to critically ill patients in the region. This collaboration reflects a broader trend in BC where local hospitals and universities partner to address practical challenges in care delivery, leveraging local innovation to improve patient outcomes.

Market Impact

While this is a clinical research story rather than a real estate or economic development report, the implications for healthcare infrastructure and operational efficiency are notable. Reduced central-line complications can lower the burden on ICU resources, potentially affecting hospital operational costs and patient flow. For the healthcare sector, this represents a shift toward evidence-based procurement of medical devices. There is no direct impact on housing markets, property values, or real estate investment in Burnaby or Vancouver from this specific clinical trial.

Builder / Developer Perspective

This clinical trial does not directly impact builder or developer feasibility, permitting, or construction costs. The study focuses on medical device efficacy in intensive care units rather than construction processes or housing policy. There is no relevant builder impact to report from this source.

BurnabyHouse Insight

The CLiCK trial underscores the importance of local clinical research in addressing critical care challenges. By bringing together clinicians, researchers, and healthcare operators, the study demonstrates how BC-based institutions can lead in medical innovation. The collaboration between Royal Columbian Hospital and Simon Fraser University highlights the value of academic-clinical partnerships in improving patient outcomes. While this does not directly affect the real estate market, it reflects the broader ecosystem of innovation and healthcare excellence in the region, which can influence regional quality of life and institutional reputation.